TrialNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2016

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines in Relapsing-Remitting Multiple Sclerosis.

Nicola S Orefice et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.